Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies

Neurology

Volumn 60, Issue 11, 2003, Pages 1852-1853

  Perry, Elaine ^a,b   McKeith, Ian ^a   Ballard, Clive ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CHOLINERGIC ACTIVITY; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; FEMALE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; TEMPORAL CORTEX;

EID: 0038792258     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000068336.84399.9E     Document Type: Article

References (10)

1. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002;47:64-70.
2. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002;110:627-639.
3. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273-277.
4. Greig NH, De Micheli E, Holloway HW, et al. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol Scand (Suppl) 2000;176:74-84.
5. Mesulam M, Guela C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722-727.
6. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993;43:1927-1934.
7. Ballard CG, McKeith IG, O'Brien K, et al. Regulation of attention and rate of progression of cognitive deficits by butyrylcholinesterase in DLB and moderate/severe Alzheimer's disease. Neurology 2002;58(suppl 3):A43.777. Abstract.
8. Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995;28:240-258.
9. Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868-876.
10. McKeith IG, Galasko D, Kosaka A, et al. Consensus guidelines for the clinical & pathological diagnosis of DLB (dementia with Lewy bodies): report of the Consortium on DLB International Workshop. Neurology 1996;47:1113-1124.